Raptor Pharmaceutical, a biopharmaceutical company focused on developing and commercializing life-altering therapeutics, has announced the commercial availability of Procysbi for nephropathic cystinosis patients in the US. The US FDA ...
Tags: US, Health&Medicine, Raptor's Procysbi
The US Food and Drug Administration (FDA) has approved Raptor's Procysbi (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children six years and older. Studies have shown that ...
Tags: Capsules, Raptor's Procysbi
The US Food and Drug Administration (FDA) has cleared Sigma-Tau Pharmaceuticals' topical ophthalmic therapeutic to treat corneal cystine crystals in cystinosis patients. The CYSTARAN 0.44% solution, which is developed in collaboration ...
Raptor Pharmaceutical has announced FDA acceptance of new drug application (NDA) for Cysteamine Bitartrate delayed-release capsules (RP103) for the potential treatment of nephropathic cystinosis. RP103 gained standard review designation ...
Tags: nephropathic cystinosis, FDA acceptance, NDA submission
Raptor Pharmaceutical has submitted a new drug application (NDA) to the FDA for marketing approval of Cysteamine Bitartrate delayed-release capsules (RP103), to treat nephropathic cystinosis. Raptor has appealed for priority review of ...
Tags: clinical trial, pharmaceutical product, new drug application